Patent infringement: JnJ, Momenta Pharma file case against Natco, Mylan Pharma
Hyderabad: Johnson & Johnson's and Momenta Pharmaceuticals have filed a lawsuit against Natco Pharma and its marketing partner Mylan Pharmaceuticals Inc. & others in the US alleging infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate Injection.
Glatiramer Acetate Injection is a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Read also: Lawsuit over Pfizer's disclosures before Chantix recall is dismissed
This lawsuit has been filed in the Pennsylvania Federal Court.
"Natco and its marketing partner, Mylan believe this is a meritless suit for a product that has been in the market for more than 5 years. Mylan and NATCO will strongly defend against this suit," Natco Pharma said in a BSE filing.
Read also: Natco Pharma dragged to Delhi HC over alleged patent violation
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.